446284-50-0

Usage

Molecular weight

195.20 g/mol

Structure

Contains a pyrrolopyridine ring with a carbonitrile group at the 7th position and a fluorine atom at the 4th position

Potential applications

Medicinal chemistry, as it may exhibit biological activities and can be used as a building block for the synthesis of other compounds

Note

Further research and testing are needed to fully understand its properties and potential uses.

Upstream product

• 446284-38-4 7-bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridine 
• 544-92-3 copper(I) cyanide 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 51173-04-7 5-fluoro-2-methoxypyridine 
• 51173-05-8 5-fluoropyridin-2-ol 
• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 652160-72-0 2-bromo-5-fluoro-3-nitropyridine 

Downstream Products

• 959321-16-5 C₂₂H₂₀FN₅O₄ 
• 959321-17-6 C₂₁H₁₈FN₅O₄ 
• 446284-56-6 4-fluoro-1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid 

Relevant academic research and scientific papers

Field-based affinity optimization of a novel azabicyclohexane scaffold HIV-1 entry inhibitor

Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend the chemotypes available. Here we demonstrate unique and differential effects of previously published antiviral compounds on the gross structure of the HIV-1 Env complex, with an azabicyclohexane scaffolded inhibitor having a positive effect on glycoprotein thermostability. We demonstrate that modification of the methyltriazole-azaindole headgroup of these entry inhibitors directly effects the potency of the compounds, and substitution of the methyltriazole with an amine-oxadiazole increases the affinity of the compound 1000-fold over parental by improving the on-rate kinetic parameter. These findings support the continuing exploration of compounds that shift the conformational equilibrium of HIV-1 Env as a novel strategy to improve future inhibitor and vaccine design efforts.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4- fluoro-7-[1,2,3]triazol-1-yl-1H-

A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycl

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.